| pubmed-article:17286393 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17286393 | lifeskim:mentions | umls-concept:C0597032 | lld:lifeskim |
| pubmed-article:17286393 | lifeskim:mentions | umls-concept:C0431085 | lld:lifeskim |
| pubmed-article:17286393 | lifeskim:mentions | umls-concept:C0010868 | lld:lifeskim |
| pubmed-article:17286393 | lifeskim:mentions | umls-concept:C0021187 | lld:lifeskim |
| pubmed-article:17286393 | lifeskim:mentions | umls-concept:C1705938 | lld:lifeskim |
| pubmed-article:17286393 | lifeskim:mentions | umls-concept:C1527178 | lld:lifeskim |
| pubmed-article:17286393 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17286393 | pubmed:dateCreated | 2007-3-2 | lld:pubmed |
| pubmed-article:17286393 | pubmed:abstractText | A series of 3-aroyl indazoles was synthesized. Modification of the C-7 position resulted in a significant structure-activity relationship (SAR) with acetylene modifications conferring unusual potency in a tumor cell cytotoxicity assay. The most potent compounds exceeded the activity of combretastatin A4 (CA-4), showing single digit nM IC50 values against all cell lines tested including those with known efflux resistance pumps. The inhibition of in vitro tubulin polymerization was comparable to CA-4, consistent with tubulin being the target for these compounds. Competition binding experiments employing [3H]colchicine and purified tubulins demonstrated that the compound specifically binds to the colchicine site. | lld:pubmed |
| pubmed-article:17286393 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17286393 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286393 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17286393 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286393 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286393 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286393 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286393 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286393 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286393 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17286393 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17286393 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:17286393 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:17286393 | pubmed:author | pubmed-author:CaiXiaohongX | lld:pubmed |
| pubmed-article:17286393 | pubmed:author | pubmed-author:MengFanyingF | lld:pubmed |
| pubmed-article:17286393 | pubmed:author | pubmed-author:DuanJian-XinJ... | lld:pubmed |
| pubmed-article:17286393 | pubmed:author | pubmed-author:HartCharlesC | lld:pubmed |
| pubmed-article:17286393 | pubmed:author | pubmed-author:LanLeslieL | lld:pubmed |
| pubmed-article:17286393 | pubmed:author | pubmed-author:MatteucciMark... | lld:pubmed |
| pubmed-article:17286393 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17286393 | pubmed:day | 8 | lld:pubmed |
| pubmed-article:17286393 | pubmed:volume | 50 | lld:pubmed |
| pubmed-article:17286393 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17286393 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17286393 | pubmed:pagination | 1001-6 | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:meshHeading | pubmed-meshheading:17286393... | lld:pubmed |
| pubmed-article:17286393 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17286393 | pubmed:articleTitle | Potent antitubulin tumor cell cytotoxins based on 3-aroyl indazoles. | lld:pubmed |
| pubmed-article:17286393 | pubmed:affiliation | Threshold Pharmaceuticals, 1300 Seaport Boulevard, Redwood City, California 94063, USA. jduan@thresholdpharm.com | lld:pubmed |
| pubmed-article:17286393 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17286393 | lld:chembl |
